INTRODUCTION {#S1}
============

Quantitatively and qualitatively distinct signals generated by engagement of the B cell receptor (BCR) and costimulatory receptors on mature B cells control their survival, metabolic reprogramming, cell-cycle entry, and proliferation ([@R50]; [@R10]; [@R76]). Indeed, the mechanisms of BCR signal transduction have been extensively studied, yet relatively little is known about how differences in the affinity and avidity of BCR engagement are encoded within the cell and precisely how these signals are then decoded to regulate these key cell-fate transitions ([@R16]; [@R51]; [@R91]). Also unknown are the mechanisms by which costimulatory or co-activating signals impact the gain of BCR signaling to fine-tune a cell's fate. Previous efforts point to a relationship between the affinity and the avidity of antigen binding to the BCR and the amplitude, duration, and periodicity of Ca^2+^ signals, and these studies reveal that distinct dynamics drive distinct fates of immature and mature B cells ([@R5]; [@R42]; [@R38]; [@R79]; [@R65]; [@R14]; [@R48]; [@R62]; [@R44]). Indeed, mutations in signal transduction proteins downstream of the BCR, notably those that mobilize Ca^2+^, can lead to altered B cell activation and differentiation, skewed humoral immune responses, autoimmune disease, and B cell malignancies (reviewed in [@R3]). Thus, Ca^2+^ serves as a central molecular switch for encoding and transducing differences in BCR signaling with significant biological and pathological consequences.

Despite the well-established importance of Ca^2+^ in the antigen-induced responses of mature B cells, current understanding is also clouded by conflicting reports regarding the consequences of variations in BCR-induced Ca^2+^ signals. Findings from a recent study suggest that in the absence of costimulation, BCR-derived Ca^2+^ signals in mature B cells initiate mitochondrial dysfunction resulting in apoptosis ([@R2]). However, others have described a dose-dependent relationship between BCR signal strength and Ca^2+^ signals, cell survival, and proliferation ([@R59]; [@R58]; [@R85]). Furthermore, the absolute role or requirement for Ca^2+^ seems to vary with the stage of mature B cell differentiation ([@R59]). For example, in germinal center (GC) B cells, the coupling between the BCR and Ca^2+^ is disrupted, and these cells rely principally on costimulatory signals to drive class switch recombination and affinity maturation ([@R57]; [@R49]). These costimulatory pathways, namely those triggered by CD40 and Toll-like receptor (TLR) engagement, are generally thought to be Ca^2+^ independent, suggesting that Ca^2+^-dependent steps of B cell differentiation may be circumvented in some cases by costimulatory signals.

Among the mechanisms that critically regulate B cell activation and differentiation, several exhibit Ca^2+^ sensitivity. These include nuclear factor kB (NF-κB) (reviewed in [@R6]; [@R28]) and NFAT ([@R72]), which control the expression of diverse genes involved in cell survival and differentiation, mTORC1 ([@R53]; [@R92]), which regulates metabolic reprogramming, and c-Myc ([@R54]), which drives proliferative expansion ([@R84]; [@R78]). In T cells, Ca^2+^ orchestrates a shift in cellular metabolism from oxidative phosphorylation to glycolysis by controlling the "master" regulators c-Myc and mTORC1 ([@R87]). However, the mechanisms by which the strength of antigen-receptor-induced quantitatively distinct Ca^2+^ signals tune steps that control B cell survival, metabolic reprogramming, cell-cycle entry, and proliferation are largely unexplored.

Consequently, we dissected the mechanisms by which Ca^2+^, and specific properties of BCR-induced Ca^2+^ signals, regulate mature B cell survival, cell-cycle entry, and proliferation. We identified a relationship between the strength of BCR engagement and amplitude and periodicity of resulting Ca^2+^ signals. Further, we established how BCR-induced Ca^2+^ signals are decoded to regulate NF-κB-dependent steps of cell survival and mTORC1-and c-Myc-dependent cell-cycle entry and proliferation. Finally, we show how CD40 or TLR9 signaling can circumvent Ca^2+^-regulated steps of B cell activation to promote enhanced survival and proliferation. Importantly, given that enhanced or constitutive BCR signaling is linked to autoimmunity and B cell malignancies ([@R42]), understanding these mechanisms that control early B cell differentiation has important implications for preventing aberrant B cell differentiation and developing therapeutics to modify the course of human disease.

RESULTS {#S2}
=======

Ca^2+^ Signals Encode BCR Signal Strength to Regulate B Cell Activation {#S3}
-----------------------------------------------------------------------

The strength of antigen-induced signaling in B lymphocytes can be modulated by varying the concentration of agonist anti-BCR antibody ([@R83]; [@R27]; [@R37]). Indeed, progressive increases in BCR signal strength are encoded as quantitatively distinct intracellular Ca^2+^ signals ([Figure 1A](#F1){ref-type="fig"}). Therefore, we varied BCR signal strength in this way to determine its relationship with Ca^2+^ and B cell activation, including survival, cell-cycle entry, and proliferation. The lowest signal strength (1 µg/mL anti-BCR) tested accentuated cell death relative to untreated cells ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}). Subsequent increases in BCR signal strength triggered a progressive increase in cell viability ([Figures 1B](#F1){ref-type="fig"} and [1C](#F1){ref-type="fig"}), cell numbers ([Figure 1D](#F1){ref-type="fig"}), the proportion of cells that divide ([Figure 1E](#F1){ref-type="fig"}), and the number of divisions per cell ([Figure 1F](#F1){ref-type="fig"}). The proportion of cells progressing beyond mid-G1 of the cell cycle, as indicated by Ki67 expression, also increased with BCR signal strength; although, at the highest anti-BCR concentration, only approximately half of B cells actively cycle at 36 h ([Figure 1G](#F1){ref-type="fig"}). Collectively, these data indicate that the strength of BCR signaling dictates whether a B cell will live or die, the efficiency of cell-cycle entry, and the extent to which they proliferate.

Given that Ca^2+^ drives the expression of fate-specific genes ([@R38], [@R39]; [@R21]; [@R59]; [@R5]), we implemented a genetic approach to examine the impact of variations in Ca^2+^ signal strength on BCR-induced gene expression. Specifically, we generated mice with a B-cell-specific (Mb1-Cre driven) deletion of *Stim1* and *Stim2* to preclude BCR-induced Orai-dependent Ca^2+^ entry. B cells from Stim1/Stim2 double-knockout (DKO) mice develop normally *in vivo* but exhibit defects in survival and proliferation *in vitro* ([@R59]; [@R58]). Consistent with these previous reports, we observed a greater rate and extent of death of *Stim1*^*fl/fl*^*Stim2*^*fl/fl*^*Mb1*^*cre*+^ (STIM DKO) by unstimulated B cells that was enhanced by BCR engagement ([Figure 1H](#F1){ref-type="fig"}). Notably, most STIM DKO B cells died without proliferating ([Figure 1I](#F1){ref-type="fig"}). Among the viable STIM DKO cells, relatively few entered the cell cycle ([Figure 1J](#F1){ref-type="fig"}) and then divided only once ([Figure 1I](#F1){ref-type="fig"}, STIM DKO, anti-BCR, lower right panel). Interestingly, this impairment in survival, cell-cycle entry, and proliferation by STIM DKO cells is comparable to the response of wild-type (WT) B cells to the lowest BCR strength tested, implying that a quantitative feature of Ca^2+^ signals, such as the initial peak amplitude, the steady-state concentration, or the frequency of spikes, tunes these responses to the BCR.

To better understand how Ca^2+^ regulates B cell fates, we quantified the impact of BCR signal strength on Ca^2+^ dynamics in mature WT and STIM DKO B cells. As anticipated, we observed a robust dose-dependent relationship between the strength of BCR engagement and the pattern of Ca^2+^ signaling ([Figure 1K](#F1){ref-type="fig"}). Specifically, the amplitude of the initial peak Ca^2+^ rise increased with BCR signal strength in both WT and STIM DKO cells, although the range was greatly attenuated in the absence of Ca^2+^ entry ([Figure 1L](#F1){ref-type="fig"}). Furthermore, in WT cells, BCR strength also induced a dose-dependent increase in steady-state Ca^2+^ levels and spike frequency. By contrast, in STIM DKO cells, while higher concentrations of anti-BCR elicited a modest increase in spike frequency, Ca^2+^ levels rapidly decayed to pre-stimulation levels at all BCR strengths. Collectively, these results indicate that Ca^2+^ entry is needed to support sustained signaling and that quantitative properties of Ca^2+^ signals reflective of the strength of BCR engagement control B cell activation by regulating cell survival, cell-cycle entry, and proliferation.

STIM/Orai-Dependent Ca^2+^ Signals Drive Bcl-xL-Dependent Rescue from Apoptosis {#S4}
-------------------------------------------------------------------------------

We next focused on the mechanism by which BCR stimulation, and specifically Ca^2+^, controls cell survival. Regardless of genotype or stimulus, nearly all nonviable B cells stained positive for Annexin V, suggesting that death of STIM DKO B cells occurs through apoptosis ([Figure 2A](#F2){ref-type="fig"}). Indeed, a pan-caspase inhibitor (zVAD-fmk) attenuated caspase-3 cleavage and cell death ([Figures 2B](#F2){ref-type="fig"} and [2C](#F2){ref-type="fig"}). Initiation of intrinsic apoptosis is dictated by a competitive equilibrium between Bcl-2 family members, including pro-apoptotic proteins and anti-apoptotic Bcl-2-like proteins ([@R24]). To evaluate whether Ca^2+^ acts to inhibit intrinsic apoptosis, we quantified its impact on the expression of four anti-apoptotic and seven pro-apoptotic genes. BCR stimulation of WT B cells led to a dramatic increase in the expression of anti-apoptotic genes *Bcl2la1* (encoding A1) and *Bcl2l1* (encoding Bcl-xL), and the induction of both genes was significantly attenuated in STIM DKO B cells ([Figures 2D](#F2){ref-type="fig"} and [S1A](#SD1){ref-type="supplementary-material"}). Notably, BCR stimulation of WT B cells also led to a modest upregulation of several pro-apoptotic genes, including *Bak*, *Bax*, *Bbc3* (encoding Puma), *Bid*, *Bim*, and *Pmaip1* (encoding Noxa). Despite the observed apoptotic phenotype of STIM DKO B cells, upregulation of four of six pro-apoptotic genes was significantly decreased in the absence of Ca^2+^ entry. This result suggests the dominant impact of BCR-induced Ca^2+^ entry is to promote survival through anti-apoptotic gene expression. Indeed, BCR stimulation led to significant upregulation of Bcl-xL protein expression ([Figure 2E](#F2){ref-type="fig"}), and the strength of BCR engagement correlated directly with the extent of its expression and viability of WT, but not DKO, cells ([Figure 2F](#F2){ref-type="fig"}). Confirming that Bcl-xL induction by Ca^2+^ is sufficient to rescue B cells from apoptosis, heterologous Bcl-xL expression substantially improved cell survival in the absence of extracellular Ca^2+^ ([Figure S1B](#SD1){ref-type="supplementary-material"}). Thus, BCR-induced Ca^2+^ signals regulate cell survival by controlling the extent of Bcl-xL protein upregulation.

Apoptosis of primary B cells can also occur through extrinsic (death receptor) mechanisms that are initiated by ligation of receptors, including TNF-related apoptosis-inducing ligand (TRAIL), Fas, and tumor necrosis factor (TNF), linked to the activation of caspase-8 ([@R30]; [@R19]). To evaluate whether BCR-induced Ca^2+^ signals also regulate extrinsic apoptosis, B cells were treated with the caspase 8 selective inhibitor z-IETD-fmk. Z-IETD-fmk did not rescue STIM DKO cells from BCR-induced apoptosis, indicating that cell-extrinsic apoptosis is unlikely to be involved in STIM DKO B cell death ([Figure S1C](#SD1){ref-type="supplementary-material"}). Importantly, although caspase-8 is a mediator of death-receptor-driven extrinsic apoptosis, it can also promote survival by preventing receptor-interacting serine/threonine protein kinase-3 (Ripk3)-dependent necroptosis ([@R75]). Thus, to definitively assess the role of caspase-8, we evaluated the kinetics of *in vitro* survival of *Ripk3*^−/−^ and *Ripk3*^−/−^*Casp8*^−/−^ B cells in the presence and absence of extracellular Ca^2+^. Although the viability of *Rip3k*^−/−^*Casp8*^−/−^ B cells was marginally increased relative to WT cells in Ca^2+^-depleted media, loss of caspase-8 and Rip3k did not restore Ca^2+^-dependent survival ([Figure S1D](#SD1){ref-type="supplementary-material"}). Given that neither caspase-8 nor Rip3k expression impact Ca^2+^-dependent rescue, we conclude that BCR-induced Ca^2+^ signals do not promote survival by antagonizing extrinsic apoptosis.

Ca^2+^-Dependent Regulation of c-Rel Activation Promotes Bcl-xL Upregulation {#S5}
----------------------------------------------------------------------------

To address how Ca^2+^ controls Bcl-xL expression, we focused on the NF-κB family member c-Rel because of its established role in BCR-induced *Bcl2l1* and *Bcl2la1* transcription ([@R80]; [@R45]; [@R86]; [@R33]; [@R69]). Consistent with a mechanistic link between Ca^2+^ and c-Rel activity, BCR-induced *Bcl2l1* ([Figure 3A](#F3){ref-type="fig"}) and Bcl-xL ([Figure 3B](#F3){ref-type="fig"}) expression and cell survival ([Figure 3C](#F3){ref-type="fig"}) were similarly impaired in c-Rel KO and STIM DKO B cells. We next asked if BCR-induced Ca^2+^ signals control the activation of c-Rel, and we found that phosphorylation of IKKβ and its target, IκBα, and degradation of IκBα were inhibited in STIM DKO B cells ([Figure 3D](#F3){ref-type="fig"}). Consistent with a block in IKK complex activation, both c-Rel and p65 nuclear localization were inhibited in STIM DKO B cells ([Figure 3E](#F3){ref-type="fig"}), as was the expression of classical NF-κB target genes, including *Nfkbia* (encoding IκBα) and *Nfkb2* (encoding p100) ([Figure 3F](#F3){ref-type="fig"}). Activation of preexisting p65 and c-Rel is critical during the initial phase of NF-κB-driven gene expression; however, *de novo* c-Rel induction is required to promote sustained NF-κB activity in lymphocytes ([@R88]; [@R4]; [@R73], [@R74]). Indeed, cells with higher c-Rel expression expressed more Bcl-xL (Pearson coefficient ᑭ = 0.48, p = 0.0; [Figure 3G](#F3){ref-type="fig"}). Moreover, Ca^2+^ regulates *de novo* transcription of *Rel*, as this and c-Rel protein induction were restrained in STIM DKO B cells ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}).

We next asked how these two distinct waves of c-Rel activity (i.e., activation of pre-existing c-Rel and *de novo Rel* expression) are regulated. Previous studies indicate that activation of existing c-Rel is regulated by calcineurin (Cn)-dependent dephosphorylation of the CARD11-BCL-10-MALT1 (CBM) complex upstream of IKK activation ([@R26]; [@R56]; [@R70]). However, various studies suggest that *de novo Rel* induction is controlled by both NFAT and NF-κB ([@R36]; [@R66]). Consistent with this model, we found that the Cn inhibitors cyclosporine A (CsA) and FK506 attenuated BCR-induced IκBα phosphorylation and degradation ([Figure S2A](#SD1){ref-type="supplementary-material"}), *Bcl2l1* mRNA ([Figure S2B](#SD1){ref-type="supplementary-material"}) and protein expression ([Figure S2C](#SD1){ref-type="supplementary-material"}), and B cell survival ([Figure S2D](#SD1){ref-type="supplementary-material"}). However, Cn also regulates NFAT activation and was required for c-Rel induction in B cells ([Figure S2E](#SD1){ref-type="supplementary-material"}). Consequently, we used IKKβ-deficient B cells to distinguish between the roles of NF-κB and NFAT in *de novo* c-Rel induction ([@R82]; [@R25]). We found that c-Rel induction was comparable in WT and IKKβ knockout (KO) (isolated from *mb1-Cre* x *Ikk2*^*fl/fl*^ mice) B cells and in both was attenuated by FK506 ([Figure S2F](#SD1){ref-type="supplementary-material"}). Together, these data establish that Ca^2+^ regulates c-Rel function by two distinct mechanisms. First, it controls IKK activity and the activation of existing c-Rel to initiate expression of NF-κB target genes, including *Bcl2l1*. Second, it promotes Cn-induced, NFAT-dependent *de novo* c-Rel expression.

Ca^2+^-Dependent mTORC1 Activation and Myc Expression Promotes Cell-Cycle Entry {#S6}
-------------------------------------------------------------------------------

In addition to its role in Bcl-xL expression and cell survival, c-Rel regulates cell-cycle entry by driving expression of proteins such as cyclin E and E2F3a ([@R11]). However, entry into and progression through the cell cycle also requires a shift in cellular metabolism from oxidative phosphorylation to aerobic glycolysis ([@R71]). We therefore asked if Ca^2+^ regulates key determinants of this metabolic reprogramming and proliferation, namely mechanistic target of rapamycin (mTOR) and c-Myc ([@R34]; [@R89]; [@R18]; [@R63]). BCR engagement elicited phosphorylation of the mTORC1 target S6 ([Figure 4A](#F4){ref-type="fig"}) and increased c-Myc expression ([Figure 4B](#F4){ref-type="fig"}) in \~40% of WT cells but significantly fewer (\~12%) STIM DKO B cells. Consistent with the established role for mTORC1 in c-Myc translation ([@R15]), the induction of pS6 and c-Myc were highly correlated. Virtually all cells with high levels of pS6 express high levels of c-Myc ([Figure 4C](#F4){ref-type="fig"}). Indeed, the mTORC1-specific inhibitor rapamycin and the pan-mTOR (mTORC1 and mTORC2) inhibitor Torin-1 both blocked BCR-induced c-Myc protein expression ([Figure S3A](#SD1){ref-type="supplementary-material"}). Furthermore, Ca^2+^ activation of mTORC1 is physiologically significant, as inhibition of mTORC1 and STIM deficiency similarly inhibited cell growth ([Figures 4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}), cell-cycle entry ([Figure 4F](#F4){ref-type="fig"}), and proliferation ([Figure 4G](#F4){ref-type="fig"} versus [Figure 1](#F1){ref-type="fig"}).

Although Ca^2+^-dependent regulation of mTORC1 likely impacts c-Myc translation, Ca^2+^ has been reported to drive *Myc* transcription ([@R87]; [@R54]; [@R66]; [@R60]). Indeed, BCR-induced *Myc* gene expression is attenuated in STIM DKO B cells ([Figure 4H](#F4){ref-type="fig"}). Given that Cn/NFAT and c-Rel are known regulators of *Myc* expression, we next explored their roles in c-Myc induction using IKKβ KO and c-Rel KO mice ([@R34], [@R36]). Interestingly, we found that BCR-induced c-Myc induction is normal in IKKβ KO B cells but blocked by FK506 and removal of extracellular Ca^2+^ ([Figure 4I](#F4){ref-type="fig"}). BCR-induced c-Myc expression is also significantly attenuated in c-Rel KO B cells ([Figure S3B](#SD1){ref-type="supplementary-material"}), indicating that both c-Rel and NFAT play primary and potentially redundant roles in c-Myc expression in mature B cells. Together, these results reveal that Ca^2+^ controls c-Myc expression by orchestrating its NFAT-and c-Rel-dependent transcription and mTORC1-regulated translation.

To address how Ca^2+^ regulates mTORC1 activity, we focused on Akt, which activates mTORC1 by inactivating the inhibitory TSC1-TSC2 complex ([@R46]; [@R53]; [@R20]; [@R9]). Interestingly, BCR-induced Akt Thr308 and TSC2 Thr1462 phosphorylation with kinetics that corresponded to the phosphorylation of S6 ([Figures 4J](#F4){ref-type="fig"} and [4K](#F4){ref-type="fig"}), and both TSC2 and S6 phosphorylation were transient in the absence of extracellular Ca^2+^. Consistent with Akt mediating Ca^2+^ control of mTORC1 activity, we also examined Foxo1 localization, which is likewise regulated by Akt ([@R8]). We found that BCR-induced Foxo1 export from the nucleus is attenuated in STIM DKO B cells ([Figure S3C](#SD1){ref-type="supplementary-material"}, left panels), WT B cells loaded with the intracellular Ca^2+^ chelator 1,2-bis-(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) (BAPTA), and WT B cells stimulated in Ca^2+^-free medium ([Figure S3C](#SD1){ref-type="supplementary-material"}, right panels). Thus, Ca^2+^ dependent Akt activation coordinately controls both TSC2 phosphorylation and cytoplasmic localization of Foxo1.

Interestingly, despite the known role for Ca^2+^ in Akt activation ([@R20]; [@R17]; [@R12]), we observed higher levels of BCR-induced Akt Thr308 phosphorylation under Ca^2+^-free conditions than in the presence of Ca^2+^ ([Figure 4J](#F4){ref-type="fig"}) and no relationship between Ca^2+^ and Akt Thr473 phosphorylation ([Figure S3D](#SD1){ref-type="supplementary-material"}). Furthermore, PDK1 (which phosphorylates Akt Thr308; [@R77]; [@R81]) is constitutively phosphorylated and exhibited no sensitivity to BCR stimulation or Ca^2+^ ([Figure 4J](#F4){ref-type="fig"}). Thus, while Ca^2+^ regulates Akt-dependent TSC2 phosphorylation, Akt Thr308 phosphorylation negatively correlates with mTORC1 activity, suggesting that Ca^2+^ control of mTORC1 is independent of Akt phosphorylation. We therefore asked if the Ca^2+^-regulated proteins CaM and Cn, which interact with Akt and the mTORC1 complex ([@R64]; [@R53]; [@R92]; [@R87]), might regulate their activity. Indeed, the CaM inhibitor W7 and the Cn inhibitor FK506 both attenuated BCR-induced S6 phosphorylation ([Figure S3E](#SD1){ref-type="supplementary-material"}). As Cn activity is regulated by CaM binding, we conclude that Ca^2+^-dependent control of mTORC1 in naive B cells is mediated by Cn-dependent regulation of Akt activity.

Ca^2+^ Signals Dynamically Tune mTORC1, NF-κB, and NFAT Activity {#S7}
----------------------------------------------------------------

Given the relationship between the strength of BCR engagement and quantitative properties of Ca^2+^ dynamics ([Figures 1K](#F1){ref-type="fig"} and [1L](#F1){ref-type="fig"}), we next asked if quantitative differences in BCR-induced Ca^2+^ signals might tune each of these key regulators of B cell activation. We began to dissect this relationship by examining the kinetics of Ca^2+^-dependent S6K phosphorylation (pS6K). In WT B cells, phosphorylation of S6K was evident 30 min after stimulation and increased for at least 90 additional minutes ([Figure 5A](#F5){ref-type="fig"}). By contrast, in STIM DKO B cells, BCR engagement induced a transient increase in pS6K that peaked at 60 min and then decayed. The transient activation of mTORC1 in STIM DKO cells suggests that mTORC1 activation may be sensitive to transient changes in cytoplasmic Ca^2+^ generated by endoplasmic reticulum (ER) release in the absence of Ca^2+^ entry ([Figure 1K](#F1){ref-type="fig"}). To further examine if ER Ca^2+^ release is responsible for this transient mTORC1 activity in STIM DKO B cells, we loaded WT B cells with the high-affinity Ca^2+^ chelator BAPTA and then cultured these cells in Ca^2+^-free medium. Under these conditions, BCR engagement failed to induce any detectable phosphorylation of S6 or S6K ([Figure 5B](#F5){ref-type="fig"}). Further evidence that the amplitude and duration of BCR-induced changes in cytoplasmic Ca^2+^ directly tune mTORC1 activity is our observation that increasing the strength of BCR engagement produced a progressive and rapid increase in S6 phosphorylation ([Figure 5C](#F5){ref-type="fig"}). Importantly, although muted relative to WT cells, the induction of pS6 in STIM DKO cells also exhibited a graded increase ([Figure 1K](#F1){ref-type="fig"}, right panel) that parallels the graded impact of BCR signal strength on the extent of Ca^2+^ release from the ER in STIM DKO cells (see [Figures 1K](#F1){ref-type="fig"} and [1L](#F1){ref-type="fig"}). Altogether, these results establish that mTORC1 activity is dynamically tuned by quantitative properties of BCR-induced Ca^2+^ signals and that the BCR-induced Ca^2+^ release from the ER can induce at least transient activation of mTORC1 in the absence of sustained Ca^2+^ entry through Orai channels.

We next sought to define the relationships among BCR signaling strength, Ca^2+^ dynamics (e.g., maximum peak, plateau, and spike frequency), and gene expression. To do this, we modulated the quantitative properties of intracellular Ca^2+^ signals by varying the extracellular \[Ca^2+^\] at a fixed level (10 µg/mL anti-BCR) of BCR engagement ([Figure 5D](#F5){ref-type="fig"}). This approach allowed us to distinguish between the impact of changing Ca^2+^ dynamics and confounding effects driven by other BCR-linked signaling pathways. We then examined the impact of these quantitatively distinct Ca^2+^ signals on the expression of NF-κB and NFAT target genes, including *Nfkbia*, *Irf4* (a previously described c-Rel target gene [@R35]), *Myc*, and *Rel*. For each of these genes ([Figure 5E](#F5){ref-type="fig"}), we observed a direct relationship between extracellular Ca^2+^ and the level of expression. A graded increase in c-Myc, Irf4, and c-Rel protein was also observed when the BCR signal strength was varied at a fixed extracellular Ca^2+^ concentration, and like phosphorylation of S6, expression of each was muted at each signal strength in STIM DKO cells ([Figure 5F](#F5){ref-type="fig"}). Together, these results establish a links among the strength of BCR engagement, quantitative properties of Ca^2+^ signals, and the pattern of NF-κB, NFAT, and mTORC1 activation. Furthermore, our results demonstrate that high-strength BCR signals can compensate to a limited extent for the absence of Ca^2+^ entry by modulating the amount of Ca^2+^ released from the ER.

Costimulatory Signals Bypass Ca^2+^ Signals to Promote Survival and Proliferation {#S8}
---------------------------------------------------------------------------------

Although BCR-induced Ca^2+^ signals drive cell survival, cell-cycle entry, and proliferation, under physiological conditions, these fates require licensing by co-activating signals. Among the best characterized is the CD40 ligand on T lymphocytes that cooperatively regulates B cell survival and proliferation during authentic immune responses ([@R57]). Therefore, we asked how CD40 signaling impacts the requirement for BCR-induced Ca^2+^ entry in cell survival and proliferation. Consistent with a previous study of STIM DKO B cells ([@R59]), CD40 engagement alone or in conjunction with the BCR dramatically improved the viability of Mb1-cre^+^ and STIM DKO B cells ([Figure 6A](#F6){ref-type="fig"} versus [Figure 1H](#F1){ref-type="fig"}) by preventing caspase-3-mediated intrinsic apoptosis ([Figures 6B](#F6){ref-type="fig"} and [6C](#F6){ref-type="fig"}). Furthermore, CD40 co-engagement dramatically increased cell growth ([Figure 6D](#F6){ref-type="fig"}) and the proportion of STIM DKO B cells that proliferate relative to BCR stimulation alone ([Figures 6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}). Notably, CD40 co-engagement failed to fully rescue cell-cycle entry ([Figure 6G](#F6){ref-type="fig"}) and proliferation of STIM DKO B cells ([Figure 6H](#F6){ref-type="fig"}). Importantly, this rescue is independent of Ca^2+^, as CD40 engagement has no impact on Ca^2+^ signaling dynamics ([Figure S4A](#SD1){ref-type="supplementary-material"}). Interestingly, stimulation with the TLR9 agonist CpG, which we previously found to mobilize cytoplasmic Ca^2+^ in B cells via scavenger-receptor-B1-mediated activation of TRPC3 channels ([@R93]), also rescued WT and STIM DKO B cells from death ([Figures S4B](#SD1){ref-type="supplementary-material"} and [S4C](#SD1){ref-type="supplementary-material"}) and rescued STIM DKO cells from impaired proliferative expansion ([Figures S4B](#SD1){ref-type="supplementary-material"} and [S4D](#SD1){ref-type="supplementary-material"}). Thus, while alternative mechanisms of mobilizing Ca^2+^ could account for the ability of CpG to fully rescue defects in survival and proliferation of STIM DKO cells, CD40 costimulation bypasses the Ca^2+^-dependent regulation of survival and proliferation ([@R93]).

CD40-Dependent Canonical NF-κB Activation Rescues B Cells from Apoptosis {#S9}
------------------------------------------------------------------------

Given the established requirement for NF-κB in B cell survival, we next asked whether CD40-mediated rescue of STIM DKO B cells from apoptosis reflects its ability to bypass Ca^2+^-dependent steps of NF-κB activation. Indeed, CD40 and BCR co-engagement induced robust IKKβ and IκBα phosphorylation and IκBα degradation in STIM DKO B cells ([Figure 7A](#F7){ref-type="fig"}). Furthermore, CD40 costimulation rescued p65 and c-Rel nuclear translocation ([Figure 7B](#F7){ref-type="fig"}) and the expression of the NF-κB-dependent genes *Nfkbia* and *Nfkb2* ([Figure 7C](#F7){ref-type="fig"}). While CD40 significantly increased *Bcl2l1* mRNA ([Figure 7D](#F7){ref-type="fig"}) and Bcl-xL protein expression ([Figure 7E](#F7){ref-type="fig"}), costimulation failed to fully rescue expression in STIM DKO B cells. Although CD40 activates both canonical and non-canonical NF-κB signaling ([@R13]), BLyS, which is a potent agonist of only non-canonical NF-κB ([@R83]), improved the survival of unstimulated B cells but did not induce Bcl-xL expression ([Figure 7E](#F7){ref-type="fig"}) or rescue viability of BCR-stimulated STIM DKO cells ([Figure 7F](#F7){ref-type="fig"}). Thus, CD40-induced activation of canonical NF-κB is the primary mechanism by which CD40 rescues STIM DKO B cells from apoptosis, but CD40 costimulation fails to fully rescue *Bcl2l1* gene expression.

Ca^2+^ Entry Is Required for Efficient c-Rel-and NFAT-Dependent Gene Expression {#S10}
-------------------------------------------------------------------------------

Finally, we asked if the ability of CD40 to partially rescue cell-cycle entry and proliferation reflects its ability to bypass the requirement for Ca^2+^ in NFAT and mTORC1 activation and c-Rel expression. While CD40 drives robust IKK-dependent activation of preexisting c-Rel ([Figure 7B](#F7){ref-type="fig"}), it did not efficiently rescue *de novo* c-Rel expression ([Figure 7G](#F7){ref-type="fig"}) or the expression of the known anti-apoptotic and pro-proliferative c-Rel targets *Bcl21l*, *Bcl2la1*, *Myc*, *Ccne1* (encoding cyclin E), and *E2f3a* (encoding E2F3) ([Figure 7H](#F7){ref-type="fig"}) in STIM DKO cells ([@R86]). The level of c-Myc induction by antigen is especially critical, as it determines the kinetics and extent of lymphocyte proliferation ([@R40]). Notably, c-Myc protein expression was comparably lower in CD40 costimulated STIM DKO and c-Rel KO cells than in WT cells ([Figure 7I](#F7){ref-type="fig"}), indicating that CD40 is unable to fully restore c-Rel-and NFAT-dependent steps of c-Myc expression despite its ability to increase TSC2 and S6 phosphorylation in the absence of Ca^2+^ ([Figure 7J](#F7){ref-type="fig"}) and pS6 in STIM DKO B cells ([Figure 7K](#F7){ref-type="fig"}).

DISCUSSION {#S11}
==========

The critical role of B cells in adaptive immunity reflects their capacity to produce antibodies that opsonize or neutralize pathogens and perform immune-regulatory functions. Although a repertoire of B cells with virtually infinite antigen specificity is generated during development, initial interactions of naive B cells with antigen and costimulatory ligands dictate cell fates and functions critical for appropriate and effective immunity. Foremost among the gaps in our understanding of these processes are (1) how variations in the affinity and avidity of antigen/antigen receptor interactions and costimulatory or coactivating signals are encoded and (2) how these signals are decoded at key developmental/differentiation stages.

Results herein establish that variations in the strength of BCR engagement are encoded as dynamic and quantitatively distinct fluctuations in the concentration of cytoplasmic Ca^2+^. We find that the strength of BCR engagement is encoded in quantitative properties of intracellular Ca^2+^ signals, specifically their peak amplitude, steady-state concentration, and spike frequency. Subsequently, these variations in Ca^2+^ dynamics control critical steps that regulate B cell survival, cell-cycle entry, and proliferation. Mechanistically, we found that BCR-induced STIM/Orai-dependent Ca^2+^ entry promotes cell survival by activating the IKK complex, thereby initiating c-Rel/p65 nuclear localization and the transcription of anti-apoptotic genes (i.e., *Bcl2l1* and *Bcl2la1*). Ca^2+^ entry also promotes Bcl-xL upregulation by increasing expression of c-Rel through NFAT-dependent transcription of *Rel*. ER release alone was insufficient to trigger IKK activation, c-Rel/p65 nuclear localization, *de novo Rel* expression, and NF-κB-dependent expression of *Bcl2l1* and *Bcl2la1*. However, CD40 stimulation or costimulation rescued STIM DKO B cells from apoptosis by activating the IKK complex. While not addressed directly here, CD40 has previously been shown to activate NF-κB signaling through TNF receptor-associated factor (TRAF)-dependent mechanisms ([@R47]; [@R1]) and our data indicate that this occurs independently of intracellular Ca^2+^ signals.

We further demonstrated that Ca^2+^ orchestrates cell-cycle entry and proliferation via mechanisms distinct from those that control cell survival. Specifically, we found that Ca^2+^ tunes the activity of mTORC1 and c-Myc; both are reported to coordinate metabolic reprogramming required for cell-cycle entry and proliferation ([@R7]; [@R90]; [@R34]; [@R87]). Optimal c-Myc expression required NFAT-and c-Rel-dependent *Myc* transcription and mTORC1-dependent Myc translation. Similarly, robust and persistent activation of mTORC1 required STIM/Orai-mediated Ca^2+^ entry, as ER release induced only transient mTORC1 activity. Loss of Ca^2+^ entry effectively decreases the strength of BCR signaling, but CD40 costimulation can circumvent the requirement for Ca^2+^ in NF-κB-and mTORC1-dependent steps of survival, cycle entry, and proliferation. Collectively, our data support a model in which the strength of BCR signaling is encoded in patterns of Ca^2+^ dynamics, which are decoded by varying the extent of NF-κB, NFAT, and mTORC1 activation.

Recent studies have identified a role for NFAT in B cell function and specifically demonstrated that STIM/Orai-dependent NFAT-driven gene expression regulates *Il10* induction by regulatory B cells to limit autoimmunity ([@R59]; [@R85]). Here, we focused on the role for Ca^2+^ in NF-κB/c-Rel-dependent functions of B cells. While the general role of c-Rel-dependent gene expression in B cell survival, cell-cycle entry, and proliferation is established ([@R33]; [@R86]; [@R69]; [@R45]; [@R29]; [@R11]; [@R41]), we show that Ca^2+^ entry regulates c-Rel-dependent gene expression first by promoting IKK complex activation and then by driving NFAT-dependent *de novo Rel* transcription. Consistent with a direct functional link between Ca^2+^ entry and c-Rel is the similar impact of c-Rel and STIM deficiency on B cell viability and proliferative dynamics *in vitro*. This linkage reflects the requisite role for c-Rel in *Bcl2l1* and *Bcl2la1* expression and G1/S progression through its regulation of c-Myc, cyclin E, and E2f3 expression ([@R11]; [@R34]). Curiously, quantitative differences in c-Rel expression impacted the extent of c-Rel target gene expression, indicating that increases in c-Rel expression in the absence of adequate IKK complex activation may be sufficient to induce or maintain c-Rel target gene expression ([@R80]). Our finding that c-Myc expression is normal in IKKβ KO B cells supports this concept as c-Rel expression levels alone can impact binding at the *Myc* promoter to regulate the efficiency of its induction ([@R23]; [@R34]). Interestingly, c-Rel KO mice exhibit defects in B cell development, germinal center maintenance, and antibody production ([@R41]; [@R28]; [@R29]) that are not observed in STIM DKO mice ([@R59]; [@R58]). Thus, the escape by STIM DKO B cells from these additional defects may reflect the ability of CD40 and TLR9 costimulation to bypass the Ca^2+^ requirement for c-Rel and p65 activation *in vivo*.

Our work also clarifies the role of Ca^2+^ entry in B cell apoptosis. Previous studies linked BCR-induced Ca^2+^ signals, in the absence of costimulation to mitochondrial dysfunction and cell death ([@R2]). In agreement, our data indicate that weak BCR signaling, induced with low concentrations of anti-BCR or by loss of STIM proteins, cause mitochondrial-dependent intrinsic apoptosis. However, our data also reveal that higher-strength BCR/Ca^2+^ signals induce sufficient expression of anti-apoptotic genes to prevent apoptosis. Furthermore, at low BCR/Ca^2+^ signal strengths, we find that CD40 signaling prevents mitochondrial-dependent apoptosis by activating the IKK complex. Thus, the extent of B cell survival is tuned by BCR signal strength and costimulatory signals.

A paradox highlighted by our results is that mice with a B-cell-specific deletion of *Stim1* and *Stim2* exhibit no apparent defect in antibody production despite decreased survival and proliferation potential *in vitro* ([@R59]; [@R58]). During T-cell-dependent (TD) immune responses, T-cell-derived signals (CD40 ligand and cytokines) facilitate B cell expansion in germinal centers. The discrepancy between the *in vivo* and *in vitro* phenotypes could reflect maturation stage-specific requirements for BCR-induced Ca^2+^ signals or the presence of factors that bypass Ca^2+^-dependent mechanisms of activation. Interestingly, germinal center B cells exhibit a cell-intrinsic block in BCR-induced Ca^2+^ signals ([@R49]). This correlates with the reported inability of germinal center B cells to efficiently activate NF-κB, mTORC1, and c-Myc in response to BCR engagement ([@R57]). CD40 costimulation, acting independently of Ca^2+^, likely compensates for this rewiring of BCR signaling to facilitate optimal NF-κB, mTORC1, and c-Myc activation ([@R57]). Thus, the capacity of CD40 to drive optimal signaling of both germinal center B cells and STIM DKO B cells represents a potential mechanism to circumvent the requirement for Ca^2+^ entry in TD antibody responses. During T-cell-independent (TI) immune responses, TI antigens induce antibody production without the help of T cells. TI antigens include type 1 (TI-1), which act as polyclonal B cell activators (e.g., CpG and lipopolysaccharide), and type 2 (TI-2), which are polysaccharides that directly crosslink the BCR (e.g., Ficoll) ([@R61]). Consistent with our *in vitro* TLR9 stimulation assays, TI-1 immune responses are normal in STIM DKO mice ([@R59]; [@R58]). In contrast, TI-2 responses are BCR mediated and would be expected to be Ca^2+^-entry dependent. However, TI-2 responses appear normal in STIM DKO mice. While not addressed here, TI-2 immune responses may require quantitatively smaller Ca^2+^ signals than those generated by STIM/Orai-mediated Ca^2+^ entry. Indeed, ablation of all three IP3 receptors (IP3R-TKO) and the attendant loss of BCR-induced ER release leads to decreased immunoglobulin M (IgM) antibody production in response to NP-Ficoll immunization ([@R85]). Additional studies are thus warranted to evaluate the cell-intrinsic role for Ca^2+^ release and entry in distinct B cell lineages, including marginal zone B cells, which are the primary mediators of the TI-2 antibody response ([@R61]).

The notion that the strength of antigen receptor engagement is reflected in distinct patterns of Ca^2+^ signaling is not new. Seminal efforts more than 20 years ago established how NFAT and NF-κB are tuned to quantitative differences in antigen-receptor-induced Ca^2+^ signals ([@R22]; [@R39]; [@R52]). Building upon this framework, we focused on developing a more comprehensive understanding of the mechanisms by which variations in Ca^2+^ signals, acting on NFAT, NF-κB, and mTORC1, regulate key steps of B cell activation (survival, cell-cycle entry, and proliferation). Furthermore, we determined how costimulatory signals, which can be generated by T cell help (CD40 ligand) or bacterial pathogen-associated molecular patterns (PAMPs) (e.g., CpG) to validate antigen authenticity, lower the BCR/Ca^2+^ threshold required to drive efficient B cell activation. It is our expectation that this new framework can be used to develop rational approaches for modulating diseases that reflect dysregulation of B cell survival and proliferation associated with immune-mediated disease and cancer.

STAR★METHODS {#S12}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S14}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bruce D. Freedman (<bruce@vet.upenn.edu>). STIM1^fl/fl^, STIM2^fl/fl^, *Mb1*-cre single transgenic mice are available from Jackson Laboratories.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S15}
--------------------------------------

All animal studies were carried out in compliance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the University of Pennsylvania and in accordance with the recommendations in the Guide and Use of Laboratory Animals of the National Institutes of Health. The animal protocol was approved by the IACUC of the University of Pennsylvania, Philadelphia, PA. C57BL/6 mice (WT) were obtained from the Jackson Laboratory. *Stim1*^fl/fl^ and *Stim2*^fl/fl^ mice ([@R68]) were a generous gift from Dr. Anjana Rao (UCSD). *Rel*^−/−^ mice ([@R55]) were obtained from Dr. Hsiou-chi Liou. *Mb1*-cre mice ([@R43]) were obtained from Dr. Michael Atchison (University of Pennsylvania) and Dr. Montserrat Anguera (University of Pennsylvania). *Ikk2*^fl/fl^ mice ([@R31]) were obtained from Dr. Michael Karen (UCSD). *Bcl2l1*^Tg^ ([@R32]) mice were obtained from Dr. Michael Cancro. 6-to 16 week old age and sex matched mice were used for all experiments.

METHOD DETAILS {#S16}
--------------

### Cell culture and stimulation {#S17}

Naive splenic B cells were purified by positive selection using CD23 coated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) followed by magnetic selection of labeled cells (B cell purity \> 95%). All primary mouse B cells were cultured in RPMI 1640 medium (BioWhittaker, Walkersville, MD) supplemented with 10% fetal bovine serum (FBS, Hyclone, Thermoscientific, Logan, Utah), 2 mM L-glutamine, penicillin (50 U/ml), streptomycin (50 U/ml), pyruvate (1 mM), MEM NEAA (100 uM), 2-ME (55 uM), HEPES (10 mM). For experiments in which B cells were stimulated in Ca^2+^ free media, 0.5 mM EGTA was added to complete RPMI media.-For *in vitro* stimulation assays, BCR was engaged using soluble 10 mg/mL anti-mouse F(ab′)2 antibody (Jackson ImmunoResearch, West Grove, PA) unless indicated otherwise. For CD40 engagement, LEAF purified anti-CD40 antibody (HM40--3, BioLegend, San Diego, CA) was used at a final concentration of 2 ug/mL. CpG (ODN1826: 5′-TCC ATG ACG TTC CTG ACG TT-3′) was synthesized and high-performance liquid chromatography purified by Integrated DNA Technologies (Coralville, IA). CpG was used at a final concentration of 1 µM. BLyS (R&D Systems, Minneapolis, MN) was used at final concentration of 100 ng/mL.

### Flow Cytometry and FACS {#S18}

Cell viability, cell size, and intracellular protein expression were measured by flow cytometry. For cell counting, 123count eBeads Counting Beads (Thermo Fisher) were used according to the manufacturer's instructions. For all flow cytometry experiments, cells were transferred to a round bottom 96 well plate, washed with FACS buffer (DPBS, 0.5% Bovine Serum Albumin, 2 mM EDTA), and stained with LIVE/DEAD Fixable Aqua Dead Cell Stain (L34957; Thermo Fisher) or LIVE/DEAD Fixable eF780 Dead Cell Stain (65--0865; Thermo Fisher) and Fc block (anti-CD16/32) prior to additional staining or fixation. Following additional processing (see below) cells were collected on an LSRFortessa or FACSCanto (BD Biosciences) and data were analyzed with FlowJo 9.9.6 software. Cells were gated on lymphocytes (by forward scatter (FSC-A) and side scatter (SSC-A), singlets (by FSC-W versus FSC-H and SSC-W versus SSC-H), and viability dye excluding cells. For analysis of *in vitro* stimulated B and T cells, cells were fixed with 4% PFA for 10 minutes followed by permeabilization with 1X Permeabilization Buffer (Thermo Scientific). Cells were stained overnight with antibodies to Myc PE (clone: D84C12, Cell Signaling), phospho-S6 PE-Cy7 (clone: D57.2.2E, Cell Signaling), c-Rel eF660 (clone: 1RE-LAH5, Thermo Scientific) or c-Rel PE (clone: REA397, Miltenyi Biotec), Irf4 PE-Vio770 (clone: REA201, Miltenyi Biotec), and/or Cleaved Caspase-3 (Asp175) (clone: 5A1E, Cell Signaling). For experiments with Bcl-xL, cells were stained for Bcl-xL (clone: 54H65, Cell Signaling) following by Alex Fluor 488 goat anti-rabbit secondary antibody (Thermo Fisher). For CFSE dilution assays, cells were washed 2X with DPBS before staining with 5 µM CFSE (Biolegend) for 6 minutes followed by the addition of FBS and 2 additional washes with complete RPMI. Labeled B cells were incubated for 72 hours in complete RPMI. CFSE dilution, viability, and cell counts were then assessed by flow cytometry. For AnnexinV apoptosis assays, cells were stained with L/D eF780 Viability dye and Annexin V FITC (Thermo Fisher) in binding buffer as described by the manufacturer.

### Immunofluorescence analysis of c-Rel, p65, and Foxo1 localization {#S19}

For immunofluorescence analysis, B cells were adhered to coverslips coated with Cell-Tak (BD Biosciences, Franklin Lakes, NJ) after stimulation. Cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.2% Triton X-100 for 5 minutes, treated with 5% BSA for 1 hour, stained with primary antibody O/N at 4C, and stained with secondary antibody at RT for 45 minutes. Nuclei were then labeled with Hoechst 33342 (Life Technologies, Cat \#H3570, 4 µg/ml), washed 3 3 5 minutes in 1% BSA in PBS, and mounted in Fluoromount B (Fisher). Images of p65, c-Rel, and Foxo1 localization were obtained with an inverted Leica SP5-II inverted (DMI6000 based) confocal microscope mounted on a Leica DMI4000 microscope (Leica Microsystems, Wetzlar, Germany) and imaging parameters were optimized independently for each channel to maintain fluorescence within the linear range while maximizing intensity resolution. Images analyzed using custom Macros in ImageJ to obtain nuclear intensities of p65, c-Rel, and Foxo1.

### Immunoblot analysis {#S20}

All cells were harvested and lysed using NP-40 lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 20mM EDTA, 1% NP-40 and complete inhibitors (1mM Sodium Orthovanadate, 1mM PMSF, 10 µg/ml Leupeptin, 5 µg/ml Aprotinin). Protein concentrations in cell lysates were determined using the Bio-Rad reagent (Bio-Rad Laboratories, Hercules, CA) and quantified in a Cary 50 Bio UV-visible Spectrophotometer. Proteins were resolved by SDS--polyacrylamide gel electrophoresis (4%--15%, Bio-Rad, Hercules, CA) then transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA). Membranes were probed with respective primary anti-mouse antibodies including S6 Ribosomal Protein (54D2) Mouse mAb, Phospho-Tuberin/TSC2 (Thr1462) Antibody, Tuberin/TSC2 (D93F12) XP® Rabbit mAb \#4308, Phospho-Akt (Thr308) (244F9) Rabbit mAb, Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb, Akt (pan) (C67E7) Rabbit mAb, Phospho-PDK1 (Ser241) (C49H2) Rabbit mAb, Phospho-p70 S6 Kinase (Thr389) (108D2) Rabbit mAb, p70 S6 Kinase (49D7) Rabbit mAb, Phospho-IKKα/β (Ser176/180) (16A6) Rabbit mAb, IKKβ (D30C6) Rabbit mAb, IKKα, Phospho-IκBα (Ser32) (14D4) Rabbit mAb, anti-IκBα (L35A5) Mouse mAb, anti-alpha-tubulin, Tuberin/TSC2 (D93F12) XP® Rabbit mAb \#4308. Blots were then incubated with Protein A HRP, anti-rabbit HRP, or anti-mouse HRP secondary antibodies (Thermo Fisher). Blots were developed with enhanced chemiluminescence using pierce ECL Western Blotting Substrate (Pierce, Rockford, IL). All immunoblots presented are from a single experiment representative of at least three independent experiments.

### Quantitative Real-Time PCR (qRT-PCR) {#S21}

cDNA was synthesized from RNA isolated (RNeasy Plus Micro Kit, QIAGEN) from cells with a high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). cDNA was amplified with on a 6500 Fast Real-Time PCR System (Applied Biosciences, Warrington, United Kingdom) using Power SYBR Green PCR Master Mix (Applied Biosciences). Ct values were obtained in triplicate for each target including *Nfkbia, Nfkb2, Myc, Rel, Irf4, Bcl2l1, Bcl2l11, Bcl2a1, Bcl2, Mcl1, Bak1, Bax, Bad, Bbc3, Bid, Pmaimp1, Ccne1, E2f3*, Ubc, *and B2M* (See [Table S1](#SD1){ref-type="supplementary-material"}). Data were analyzed with the instrument software v1.3.1 (Applied Biosystems, Warrington, United Kingdom). All plots show relative expression based on difference between stimulated and unstimulated samples. For all plots mean ± 95% confidence interval is shown.

### Calcium Imaging {#S22}

Mouse B cells (5 million/mL) were loaded with 3 µM fura-2 acetoxymethyl ester (Molecular Probes, Eugene, OR) in external solution containing 145mM NaCl, 4.5mM KCl, 2mM CaCl~2~, 1mM MgCl~2~, 10mM glucose, 10mM HEPES, 2mM glutamine, and 2% fetal bovine serum (Hyclone, ThermoScientific, Logan, Utah) for 10 minutes at 25°C. Cells were adhered to coverslips coated with Cell-Tak (BD Biosciences, Franklin Lakes, NJ), mounted on the stage of a Leica DMI6000 microscope configured with a Photometrics Evolve 512 Camera (Tucson, AZ) using an Olympus 40x oil objective (Shinjuku, Tokyo, Japan), and images were acquired with MetaFluor software (Molecular Devices, Downingtown, PA). The cells were then perfused with the balanced salt solution prior to addition of 10 µg/ml anti-IgM. Ca^2+^ mobilization was analyzed by plotting the emission ratio of 340/380-nm excitation for each cell. Each plot is the averaged ratio from at least 30 cells and is representative of at least 3 independent experiments. Analysis of Fura-2 ratios was completed in MATLAB (Mathworks, Massachusetts, USA) using custom written scripts. Maximum Fura-2 ratios were identified by calculating the maximum value within the first 5 minutes of recording and subtracting the average Fura-2 ratio from the first 0.5 minutes for each cell. The plateau value was measured by calculating the median Fura-2 ratio for each cell during the final 5 minutes of recording (10 min -- 15 minutes). Spike interval number was calculated by detecting local minima and maxima and determined the absolute magnitude between the two local extrema. A fura-2 ratio "spike" threshold of 0.075 was identified as most accurate for spike detection. The total number of spikes were determined throughout the recording. Data visualization was performed using the statistical computing environment, R (v3.5.1), and RStudio (v1.1.456).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S23}
---------------------------------------

Significance for all statistical tests was determined at p values \< 0.05 and is shown as \* for p \< 0.05, \*\* for p \< 0.01, and \*\*\* for p \< 0.001 in all figures except for qPCR data in which 95% confidence intervals were used. All data were assessed for normality using probability plots and the Kolmogorov-Smirnov test for normality. Normal distributions were compared using either two-tailed Student's t test or Welch's t test (depending on equality of variance) and non-normal data were compared using Wilcoxon rank sum test. The correlation between c-Rel and Bcl-xL expression was determined by calculating the Pearson correlation coefficient in WT anti-BCR stimulated samples. Unless otherwise indicated, results are representative of at least three independent experiments.

DATA AND CODE AVAILABILITY {#S24}
--------------------------

This study did not generate/analyze relevant datasets.
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![Ca^2+^ Signals Encode BCR Signal Strength to Regulate B Cell Activation\
(A) Fura-2 ratiometric imaging of intracellular Ca^2+^ in WT CD23^+^ B cells stimulated with anti-BCR as indicated. Average results are representative of three independent experiments with \>50 cells per condition.\
(B) CFSE-labeled WT CD23^+^ B cells were stimulated in complete media with anti-BCR for 72 h as indicated. Carboxyfluorescein succinimidyl ester (CFSE) dilution and live/dead plots are representative of triplicate experiments.\
(C and D) Viability of WT CD23^+^ B cells as determined by the proportion of live/dead cells at 22 h (C) and total number of live cells at each initial anti-BCR concentration for each time point (D) (mean ± SD from triplicate wells).\
(E and F) The proportion of divided cells (E) and average division number (F) for data shown in (B) (mean ± SD from triplicate wells).\
(G) Ki67 expression in WT CD23^+^ B cells stimulated for 32 h with anti-BCR as indicated (mean percentage ± SD from triplicate wells; statistical comparisons to adjacent \[lower\] concentration of anti-BCR).\
(H) Total cell counts at indicated times are plotted for each condition (mean cell number ± SD of triplicate wells). CFSE-labeled CD23^+^ B cells from *Stim1*^*wt/*^ *wtStim2*^*wt/wt*^*Mb1*^*cre*+^ (Mb1-Cre) and *Stim1*^*fl/fl*^*Stim2*^*fl/fl*^*Mb1*^*cre+*^ (STIM DKO) mice were unstimulated or stimulated for 72 h with anti-BCR. (I)C FSE dilution versus live/dead plot (left) is representative of results from triplicate wells (right) at 72 h.\
(J) Ki67 expression (mean ± SD of triplicate wells) 32 h after anti-BCR stimulation of WT and STIM DKO B cells.\
(K) Fura-2 ratiometric imaging of cytoplasmic \[Ca^2+^\] in WT and STIM DKO B cells stimulated with anti-BCR as indicated. Each line depicts the response of a single cell.\
(L) Boxplot representation of mean initial peak (upper left), average sustained concentration (between 10 and 15 min, upper right), and total spikes (lower left) in WT and STIM DKO B cells. Results are representative of three independent experiments with \>50 cells per genotype/treatment, and statistical comparisons were made to adjacent (lower) concentration of anti-BCR. For all figures, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1584935-f0001){#F1}

![STIM/Orai-Dependent Ca^2+^ Signals Promote B Cell Survival through Induction of Bcl-xL Expression\
WT and STIM DKO CD23^+^ B cells were cultured in complete media in the absence or presence of anti-BCR.\
(A) Annexin V and live/dead staining at 24 h of culture. (Left) Representative plot (right) and quantification of mean percentage of Annexin-V-stained cells (±SD from triplicate wells) are shown. (B and C) Flow cytometric analysis of intracellular cleaved caspase-3 at 12 h. The impact of the pan-caspase inhibitor zVAD-fmk (100 µM) on B cell viability was determined 12 h after anti-BCR stimulation.\
(B) Representative cytometry plot (B) and percentage (mean ± SD) of cleaved caspase-3-stained cells from triplicate wells (C).\
(D) Heatmap shows relative gene expression of anti-and pro-apoptotic genes based upon qRT-PCR analysis following culture as indicated for 6 h. Average expression from triplicate wells relative to Mb1-cre unstimulated (controls).\
(E) Intracellular Bcl-xL expression (Fluorescence minus one (FMO), gray shaded histogram, left) in anti-BCR stimulated WT and STIM DKO B cells at 6 h (right, Bcl-xL MFI ± SD from triplicate wells).\
(F) Bcl-xL mean fluorescence intensity (6 h) in CD23^+^ B cells from WT (black line) and STIM DKO (red line) mice stimulated with anti-BCR (at indicated concentration) plotted versus viability (24 h, % live cells ± SD from triplicate wells and duplicate cultures). For all figures, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1584935-f0002){#F2}

![Ca^2+^ Entry Regulates NF-κB-Dependent Anti-apoptotic Gene Expression\
(A) *Bcl2l1* expression after 6 h of anti-BCR stimulation in CD23^+^ B cells from WT and c-Rel KO mice (mean ± 95% confidence interval; \*, statistically significant).\
(B) Intracellular Bcl-xL protein levels (relative to FMO, gray shaded histogram) in CD23^+^ B cells from WT (black line), STIM DKO (gray line), and c-Rel KO (red line) mice 6 h after anti-BCR stimulation (left) and mean (median flourescence intensity (MFI) ± SD from triplicate wells) Bcl-xL fluorescence intensity (right).\
(C) CD23^+^ B cells from WT (solid line) and c-Rel KO (dashed line) mice were cultured for indicated times in media alone or media containing anti-BCR. The total number of live cells was enumerated, and mean cell number (±SD of triplicate wells) is plotted for the indicated time points.\
(D) Immunoblot of anti-BCR-dependent NF-κB activation in CD23^+^ WT and STIM DKO B cells at indicated time points.\
(E) p65 (top) and c-Rel (bottom) nuclear localization in unstimulated (media) and anti-BCR stimulated (2 h) WT (black) and STIM DKO (white) B cells. Overlay of average c-Rel and p65 nuclear cell intensity (\>70 cells per group) is shown.(F) *Nfkbia* (IκBα) and *Nfkb2* (p100) mRNA expression in CD23^+^ B cells from WT and STIM DKO mice cultured for 3 h in the presence or absence of anti-BCR (mean ± 95% confidence interval; \*, statistically significant).\
(G) Scatterplot of c-Bcl-xL and Rel expression in individual WT (left) and STIM DKO (right) B cells cultured in the absence (media) and presence of anti-BCR for 20 h.\
(H) Time course of anti-BCR-induced *Rel* expression in CD23^+^ B cells from WT and STIM DKO mice (mean ± 95% confidence interval; \*, statistically significant).\
(I) c-Rel expression in WT (black line) and STIM DKO (red line) B cells cultured for 12 h with anti-BCR. (Left) Mean c-Rel MFI (±SD from triplicate wells, right). For all figures except where indicated, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1584935-f0003){#F3}

![Ca^2+^ Is Required for mTORC1-and Myc-Dependent Cell-Cycle Entry\
(A and B) Intracellular phosphorylated S6 (pS6) (A) and c-Myc protein expression (B) in WT and STIM DKO at 4 h of stimulation with anti-BCR (mean percentage ± SD from triplicate wells).\
(C) pS6 expression in Myc^+^ and Myc^---^ B cells (top, from B) and Myc expression in phospho-S6 ''high'' and phospho-S6 ''low'' populations (bottom, from A).\
(D) Cell size (Forward scatter area or FSC-A) of anti-BCR-stimulated WT and STIM DKO B cells (32 h) and impact of the mTORC1 inhibitor rapamycin (25 nM).\
(E) Cell size from (D) (mean FSC-A ± SD from triplicate wells).\
(F) Ki67 expression (mean ± SD of triplicate wells) in WT and STIM DKO B cells following 32 h of anti-BCR and the impact of rapamycin (25 nM).\
(G) CFSE dilution analysis of the proliferative dynamics of anti-BCR-stimulated WT B cells in the absence or presence of rapamycin (25 nM) or torin-1 (100 nM). Results are representative of triplicate measurements.\
(H) Time course of *Myc* expression in CD23^+^ B cells from WT (black line) and STIM DKO (red line) mice stimulated with anti-BCR (mean ± 95% confidence interval; \*, statistically significant).\
(I) c-Myc expression in CD23^+^ B cells from *Ikk2*^fl/fl^ 3 *Mb1cre*^---^ (WT, black line) and *Ikk2*^fl/fl^ 3 *Mb1cre*^+^ (IKKβ KO, red line) mice stimulated with anti-BCR (6 h) in the absence or presence of FK506 (1 µM). Mean percentage of Myc^+^ cells (±SD of triplicate measurements) is shown.\
(j) Immunoblot of mTORC1 activity in B cells stimulated with anti-BCR in the presence and absence of extracellular Ca^2+^.\
(K) Densiometric analysis of phospho-TSC2-Thr1462 and phospho-S6 (from J). For all figures, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1584935-f0004){#F4}

![BCR-Induced Ca^2+^ Signals Tune mTORC1, NF-κB, and NFAT Activity\
(A) Immunoblot analysis of S6 kinase phosphorylation (pS6K) in WT and STIM DKO B cells following stimulation with anti-BCR for times indicated.\
(B) pS6K and S6 phosphorylation (pS6) following anti-BCR stimulation of WT B cells cultured in media containing 0 mM Ca^2+^ and 2 mM Ca^2+^ and in cells loaded with membrane-permeant Ca^2+^ chelator (BAPTA) in 0 mM Ca^2+^ medium.\
(C) Anti-BCR dose dependence of pS6 in WT and STIM DKO at 6 h (mean percentage ± SD from triplicate wells are representative of two independent experiments).\
(D) Boxplot representation of initial peak (left), average plateau/sustained concentration (from 10 to 15 min after anti-BCR, middle), and total Ca^2+^ spikes (20-min interval, right) in WT B cells stimulated in media containing indicated \[Ca^2+^\]. Results are representative of three independent experiments with \>50 cells per genotype and treatment.\
(E) Extracellular Ca^2+^ dependence of *Rel*, *Nfkbia*, *Myc*, and *Irf4* mRNA expression 4 h after anti-BCR stimulation in media containing 0, 0.05, 0.2, 0.5, and 2.0 mM Ca^2+^ (mean ± 95% confidence interval; \*, statistically significant).\
(F) Anti-BCR dose-dependent expression of c-Myc, Irf4, and c-Rel protein in WT and STIM DKO at 6 h (mean percentage ± SD of triplicate measurements; representative of at least two independent experiments0.\
For (C), (D), and (F), statistical significance was determined relative to preceding concentration of anti-BCR or extracellular \[Ca^2+^\]. For all figures, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1584935-f0005){#F5}

![CD40 Costimulation Promotes B Cell Survival and Proliferation\
(A) D23^+^ B cells from WT (black) and STIM DKO (red) mice were cultured for indicated times in media containing anti-CD40 ± anti-BCR. The total number of live cells was enumerated, and mean cell numbers (±SD of triplicate wells) are plotted for the indicated time points.\
(B) Intracellular cleaved caspase-3 in live and dead anti-BCR-stimulated WT and STIM DKO B cells (24 h).\
(C) Frequency of cells containing cleaved caspase-3 from (B) (mean percentage ± SD of triplicate measurements).\
(D) Cell size (FSC-A) analysis of WT and STIM DKO B cells stimulated with anti-BCR and anti-CD40 (results from triplicate wells and two independent experiments).\
(E) CFSE dilution and live/dead analysis of WT and STIM DKO CD23^+^ B cells stimulated as indicated for 72 h. Plots are representative of results from triplicate wells.\
(F) Total live cells from (E) (mean ± SD from triplicate wells).\
(G) Ki67 expression in WT and STIM DKO B cells following 32-h stimulation with anti-BCR in the absence or presence of anti-CD40 (mean percentage ± SD of Ki67^+^ cells from triplicate wells from at least two independent experiments).\
(H) Percentage of divided cells and mean division number for data shown in (E) (mean ± SD from triplicate wells).\
For all figures, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1584935-f0006){#F6}

![Ca^2+^-Independent Activation of Canonical NF-κB and mTORC1 by CD40 Promotes B Cell Survival and Proliferation\
(A) Immunoblot analysis of canonical NF-κB activation in CD23^+^ WT and STIM DKO B cells stimulated with anti-BCR and anti-CD40 at indicated time points.\
(B) NF-κB p65 (left) and c-Rel (right) nuclear intensity in WT (black) and STIM DKO (white) B cells (\>70 cells per group) stimulated as indicated.\
(C and D) (C) *Nfkbia* (IκBα) and *Nfkb2* (p100) and (D) *Bcl2l1* (Bcl-xL) mRNA expression in CD23^+^ B cells from WT and STIM DKO mice stimulated for 3 h with anti-CD40 alone or anti-CD40 and anti-BCR (mean ± 95% confidence interval; \*, statistically significant).\
(E) Bcl-xL expression in WT (black line) and STIM DKO (red line) B cells after 6 h of anti-BCR in the absence or presence of BLyS (100 ng/mL) and the absence or presence of anti-CD40 (left) and plot of mean Bcl-xL MFI (±SD) from triplicate wells (right).\
(F) Impact of BLyS (100 ng/mL) on the viability of unstimulated and anti-BCR-stimulated WT and STIM DKO B cells (mean cell number ± SD of triplicate wells).\
(G) c-Rel expression in WT (black line) and STIM DKO (red line) B cells stimulated as indicated for 12 h. Average MFI (±SD) of triplicate wells (right) is shown.\
(H) Expression of c-Rel target genes *Bcl2a1* (A1), *Ccne1* (Cyclin E), *Myc* (c-Myc), *Bcl2l1*, and *E2f3a* (E2f3) in WT (black) and STIM DKO B cells (red) 24 h following stimulation with anti-BCR and anti-CD40 (mean ± 95% confidence interval; \*, statistically significant).\
(I) c-Myc expression in WT (black line), STIM DKO (red line), and c-Rel KO (gray) B cells following 20 h of culture with no stimulus (media), anti-BCR, or anti-BCR/CD40.\
(J) Immunoblot of mTORC1 activity in B cells stimulated with anti-BCR and anti-CD40 in Ca^2+^ containing (2 mM) or Ca^2+^-free medium.\
(K) Plot of phospho-S6 (pS6)-positive WT (black) and STIM DKO (red) B cells at 20 h of anti-BCR or anti-BCR/CD40 stimulation (mean percentage ± SD from triplicate wells). For all figures except where indicated, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.](nihms-1584935-f0007){#F7}

###### KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                                                                     SOURCE                                                                    IDENTIFIER
  --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ---------------------------------------------------
  Antibodies                                                                                                                                                                                                        
                                                                                                                                                                                                                    
  anti-FoxO1 (C29H4) Rabbit mAb                                                                                                           Cell Signaling                                                            Cat\#2880S; RRID:AB_2106495
  anti-c-Myc PE (D84C12)                                                                                                                  Cell Signaling                                                            Cat\#14819 RRID:AB_2798629
  S6 Ribosomal Protein (54D2) Mouse mAb                                                                                                   Cell Signaling                                                            Cat\#2317 RRID:AB_2238583
  Phospho-Tuberin/TSC2 (Thr1462) Antibody                                                                                                 Cell Signaling                                                            Cat\#3611 RRID:AB_329855
  Phospho-Akt (Thr308) (244F9) Rabbit mAb                                                                                                 Cell Signaling                                                            Cat\#4056 RRID:AB_331163
  Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb                                                                                               Cell Signaling                                                            Cat\#4060S
  Akt (pan) (C67E7) Rabbit mAb                                                                                                            Cell Signaling                                                            Cat\#4691 RRID:AB_915783
  Phospho-PDK1 (Ser241) (C49H2) Rabbit mAb                                                                                                Cell Signaling                                                            Cat\#3438 RRID:AB_2161134
  Phospho-p70 S6 Kinase (Thr389) (108D2) Rabbit mAb                                                                                       Cell Signaling                                                            Cat\#9234 RRID:AB_2269803
  p70 S6 Kinase (49D7) Rabbit mAb                                                                                                         Cell Signaling                                                            Cat\#2708 RRID:AB_10694087
  Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb                                                                                            Cell Signaling                                                            Cat\#9664 RRID:AB_2070042
  Phospho-IKKα/β (Ser176/180) (16A6) Rabbit mAb                                                                                           Cell Signaling                                                            Cat\#2697 RRID:AB_2079382
  IKKβ (D30C6) Rabbit mAb                                                                                                                 Cell Signaling                                                            Cat\#8943 RRID:AB_11024092
  Phospho-IκBα (Ser32) (14D4) Rabbit mAb                                                                                                  Cell Signaling                                                            Cat\#2859 RRID:AB_561111
  IκBα (L35A5) Mouse mAb (Amino-terminal Antigen) \#4814                                                                                  Cell Signaling                                                            Cat\#4814S RRID:AB_390781
  anti-alpha-tubulin                                                                                                                      Sigma Aldrich                                                             Cat\#T1568
  anti-Ki67                                                                                                                               Millipore Sigma                                                           Cat\#AB9260
  Tuberin/TSC2 (D93F12) XP® Rabbit mAb                                                                                                    Cell Signaling                                                            Cat\#4308 RRID:AB_10547134
  anti-phospho-S6 PE-Cy7 (D57.2.2E)                                                                                                       Cell Signaling                                                            Cat\#34411S RRID:AB_2799051
  anti-c-Rel eF660 (1RELAH5)                                                                                                              Thermo Scientific                                                         Cat\#50--6111-80 RRID:AB_2574261
  anti-c-Rel PE (REA397)                                                                                                                  Miltenyi Biotec                                                           Cat\#130--124-715 RRID:AB_2651454
  Anti-IRF-4-PE-Vio770                                                                                                                    Miltenyi Biotec                                                           Cat\#130--100-909 RRID:AB_2652519
  anti-Bcl-xL (54H6)                                                                                                                      Cell Signaling                                                            Cat\# 2764S RRID:AB_2228008
  Alex Fluor 488 goat anti-rabbit secondary antibody                                                                                      Thermo Fisher                                                             Cat\#A11008 RRID:AB_143165
  AffiniPure F(ab′)2 Fragment Goat Anti-Mouse IgM, Mu Chain Specific                                                                      Jackson ImmunoResearch                                                    Cat\#115--006-020 RRID:AB_2338469
  LEAF Purified anti-mouse CD40 antibody (HM40--3)                                                                                        BioLegend                                                                 Cat\#102908 RRID:AB_312951
  Purified anti-mouse CD16/32 Antibody                                                                                                    BioLegend                                                                 Cat\#101302 RRID:AB_312801
  Protein A HRP                                                                                                                           Cell Signaling                                                            Cat\#12291
  Goat anti-Rabbit IgG (H+L) Secondary Antibody, HRP                                                                                      Thermo Fisher                                                             Cat\#65--6120 RRID:AB_2533967
  Goat anti-Mouse IgG (H+L) Secondary Antibody, HRP                                                                                       Thermo Fisher                                                             Cat\#62--6520 RRID:AB_88369
                                                                                                                                                                                                                    
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                                                                     
                                                                                                                                                                                                                    
  CFSE                                                                                                                                    Biolegend                                                                 Cat\#423801
  Fura-2AM                                                                                                                                Molecular Probes                                                          CAS 108964--32-5
  FK506 (tacrolimus)                                                                                                                      Tocris Bioscience                                                         Cat\#3631/10
  Cyclosporine A                                                                                                                          Tocris Bioscience                                                         Cat\#1101
  Torin-1                                                                                                                                 Tocris Bioscience                                                         Cat\#4247
  Rapamycin (Sirolimus)                                                                                                                   Selleck Chemical                                                          Cat\#S1039
  W-7 hydrochloride                                                                                                                       Tocris Bioscience                                                         Cat\#0369
  Fluoromount G                                                                                                                           Molecular Probes                                                          CAS 108964--32-5
  eBioscience Permeabilization Buffer (10X)                                                                                               Thermo Fisher                                                             Cat\#00--8333-56
  Paraformaldehyde Aqueous Solution ---16%                                                                                                Electron Microscopy Systems                                               CAS \#30525--89-4
  Corning Cell-Tak Cell and Tissue Adhesive                                                                                               Fisher Scientific                                                         Cat\#CB40240
  Hoechst 33342                                                                                                                           Life Technologies                                                         Cat\#H3570
  LIVE/DEAD Fixable Aqua Dead Cell Stain                                                                                                  Thermo Fisher                                                             Cat\#L34957
  LIVE/DEAD Fixable eF780 Dead Cell Stain                                                                                                 Thermo Fisher                                                             Cat\#65--0865
  Annexin V, FITC conjugate                                                                                                               Thermo Fisher                                                             Cat\#A13199
                                                                                                                                                                                                                    
  Critical Commercial Assays                                                                                                                                                                                        
                                                                                                                                                                                                                    
  CD23 MicroBeads, mouse                                                                                                                  Miltenyi Biotec                                                           Cat\#130--098-784
  RNeasy Micro Kit                                                                                                                        QIAGEN                                                                    Cat\#74034
  PERFECTA SYBR SMX L-ROX                                                                                                                 VWR                                                                       Cat\#101414--168
  High-Capacity RNA-to-cDNA Kit                                                                                                           Applied Biosystems                                                        Cat\#4387406
  AccuStart II GelTrack PCR SuperMix, QuantaBio                                                                                           VWR                                                                       Cat\#76047--140
                                                                                                                                                                                                                    
  Experimental Models: Organisms/Strains                                                                                                                                                                            
                                                                                                                                                                                                                    
  *Mouse: Bcl-xL Tg: B6.Bcl2l1*^Tg^ mice                                                                                                  [@R32]                                                                    N/A
  Mouse: Stim1^fl/fl^Stim2^fl/fl^: B6(Cg)-*Stim1*^*tm1Rao*^/J *Stim2*^*tm1Rao*^/J                                                         [@R68]                                                                    N/A
  Mouse: Mb1-cre(Stim1^fl/fl^Stim2^fl/fl^): B6(Cg)-*Stim1*^*tm1Rao*^/J x*Stim2*^*tm1Rao*^/J x B6.C(Cg)-*Cd79a*^*tm1(cre)*^ *Reth*/EhobJ   This paper                                                                N/A
  Mouse: Ikk2^fl/fl^                                                                                                                      [@R31]                                                                    N/A
  Mouse: Mb1-cre(Ikk2^fl/fl^)                                                                                                             This paper                                                                N/A
  Mouse: C57BL/6J                                                                                                                         Jackson Laboratory                                                        N/A
  Mouse: Ripk3^−/−^Casp8^−/−^                                                                                                             [@R67]                                                                    N/A
  Mouse: Mb1-cre+: B6.C(Cg)-*Cd79a*^*tm1(cre)Reth*^/EhobJ                                                                                 [@R43]                                                                    N/A
  Mouse: Rel^−/−^                                                                                                                         [@R55]                                                                    N/A
                                                                                                                                                                                                                    
  Oligonucleotides                                                                                                                                                                                                  
                                                                                                                                                                                                                    
  qRT-PCR Primers                                                                                                                         See [Table S1](#SD1){ref-type="supplementary-material"} for all primers   N/A
                                                                                                                                                                                                                    
  Software and Algorithms                                                                                                                                                                                           
                                                                                                                                                                                                                    
  ImageJ                                                                                                                                  ImageJ                                                                    <https://imagej.net/ImageJ>
  Flow Jo_v9                                                                                                                              Flow Jo                                                                   [https://www.flowjo.com](https://www.flowjo.com/)
  Rstudio_v1.1.456                                                                                                                        Rstudio                                                                   <https://rstudio.com/>
  R_v3.5.1                                                                                                                                R                                                                         <https://www.r-project.org/>
  *Bioconductor_v3.10*                                                                                                                    Bioconductor                                                              <https://www.bioconductor.org/install/>
  Matlab_R2017b                                                                                                                           MATLAB                                                                    <https://www.mathworks.com/products/matlab.html>

###### Highlights

-   BCR signal strength is encoded as quantitatively distinct intracellular Ca^2+^ signals

-   Ca^2+^ dynamics are decoded by NF-κB, NFAT, and mTORC1 to drive cell fates

-   BCR-induced Ca^2+^ signals are required for maximal B cell survival and proliferation

-   CD40 compensates for weak BCR/Ca^2+^ signals to rescue NF-κB-and mTORC1-dependent fates
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